BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
NCT05935098
Recruiting
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors. Key details of the study include: * The study is expected to last about 36 months. * Participants will receive treatment until they either no longer benefit from the treatment, experience side effects that are too severe, or choose to stop participating.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Advent Health Cancer Institute, Orlando, Florida +25 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Register for Updates
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283
Recruiting
This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +63 locations
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
NCT06189807
Recruiting
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CKD, Chronic Kidney Diseases
Register for Updates
Virtual Walking Therapy for Neuropathic Pain Following Incomplete Spinal Cord Injury
NCT06330181
Recruiting
The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Texas A&M University, College Station, Texas
Conditions: Spinal Cord Injuries, Neuropathic Pain
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Research Site, Los Angeles, California +25 locations
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: City of Hope National Medical Center, Duarte, California +12 locations
Conditions: Advanced Solid Tumors
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Pa0016 50662, Gilbert, Arizona +112 locations
Conditions: Psoriatic Arthritis
Register for Updates
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017
Recruiting
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +2 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962
Recruiting
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2025
Locations: University of California, San Francisco, San Francisco, California +6 locations
Conditions: Crohns Disease
Register for Updates
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932
Recruiting
The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California +14 locations
Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
The THRIVE Study: Teaching Healthy Regulation in Individuals & Vulnerable Environments
NCT06821035
Recruiting
The goal of this 2-arm randomized control trial is to determine the impact of a community health worker delivered coaching intervention, GRIT, on preventing the early initiation of regular use of alcohol and cannabis among adversity-impacted adolescents ages 11-14 who do not regularly use alcohol or cannabis at baseline. The specific aims include: * Aim 1. Examine the effect of GRIT on preventing the early initiation of regular alcohol and cannabis use over time. * Aim 2. Examine the role of yo... Read More
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
04/10/2025
Locations: The Regents of the University of California, Irvine, Irvine, California
Conditions: Adverse Childhood Experiences, Family Functioning
Register for Updates
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
NCT06877702
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/10/2025
Locations: ICON Lenexa, Lenexa, Kansas +1 locations
Conditions: Healthy Volunteers
Register for Updates